RxDoctor Payments DataLook up a doctor →

Robert Hopkin, MD

Clinical Genetics (M.D.) · Cincinnati, OHNPI 1447281878

Payments from drug & device makers

$2,857,545in general payments, 2019–2025

Across 707 payments — averaging $4041.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amicus Therapeutics, Inc.$1.4M
  • Sanofi$866K
  • Sanofi US Services Inc.$267K
  • Chiesi USA, Inc.$184K
  • Radius Health, Inc.$42K
  • Sanofi-aventis U.S. LLC$31K
  • plus $30K from 5 others
$5,955in research payments, 2019–2025

Across 14 payments — averaging $425.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi$6K

What the payments were for

  • Consulting fees$167,44040%
  • Speaking & faculty fees$146,14035%
  • Travel & lodging$101,06324%
  • Food & beverage$4,4321%
  • Education$10%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,857,545 in reported general payments places this provider in the 95th percentile of 42 clinical genetics (m.d.) providers in Ohio.

See all clinical genetics (m.d.) providers in Ohio

Medicare billing

Part B allowed, 2024
$1,837
Medicare patients
14
Services billed
15

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GalafoldMigalastat Hcl39$1,198,535
FabrazymeAgalsidase Beta44$503,023
ElfabrioPegunigalsidase Alfa-Iwxj12$444,173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amicus Therapeutics, Inc.Galafold$1,437,898$1,198,53539 claims
SanofiFabrazyme$865,565$503,02344 claims
Chiesi USA, Inc.Elfabrio$184,402$444,17312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 42 clinical genetics (m.d.) providers in Ohio.

Other clinical genetics (m.d.) in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →